EULAR Revenue and Competitors
Estimated Revenue & Valuation
- EULAR's estimated annual revenue is currently $12.3M per year.
- EULAR's estimated revenue per employee is $140,000
Employee Data
- EULAR has 88 Employees.
- EULAR grew their employee count by 9% last year.
EULAR's People
| Name | Title | Email/Phone |
|---|
EULAR Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $14.1M | 101 | 5% | N/A | N/A |
#2 | $1.6M | 19 | -71% | N/A | N/A |
#3 | $212.8M | 1063 | 5% | $65M | N/A |
#4 | $6.8M | 54 | 8% | N/A | N/A |
#5 | $12.9M | 92 | 2% | $23.1M | N/A |
#6 | $1M | 12 | N/A | N/A | N/A |
#7 | $106.5M | 599 | -17% | $2.3M | N/A |
#8 | $35.6M | 231 | 6% | N/A | N/A |
#9 | $38.3M | 249 | 5% | N/A | N/A |
#10 | $45M | 299 | -4% | $102.6M | N/A |
What Is EULAR?
The European Alliance of Associations for Rheumatology, EULAR, is the organisation which represents the people with arthritis/rheumatism, health professionals in rheumatology (HPR) and scientific societies of rheumatology of all the European nations. EULAR aims to reduce the impact of rheumatic and musculoskeletal diseases (RMDs) on the individual and society and to improve the social position and the quality of life of people with rheumatic and musculoskeletal diseases in Europe. To this end, EULAR stimulates, promotes and supports education, research, prevention and treatment of rheumatic and musculoskeletal diseases. These include the diseases of the musculoskeletal or locomotor system as well as systemic immune mediated diseases.
keywords:N/A
N/A
Total Funding
88
Number of Employees
$12.3M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EULAR News
... require a multidisciplinary approach, according to joint guidelines released by EULAR and the American College of Rheumatology.
EULAR/ACR Releases Points-to-Consider for Management of Autoinflammatory Type I Interferonopathies (CANDLE/PRAAS, SAVI, and AGS). Dhivya...
The full report was published in Annals of the Rheumatic Diseases. The recommendations were developed by a EULAR taskforce using an evidence-...